Review article: Fructose in non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 10, 2012, Pages 1135-1144

  Yilmaz, Y ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHOSPHOFRUCTOKINASE; ADVANCED GLYCATION END PRODUCT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERULOPLASMIN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C OXIDASE; ENDOTOXIN; FATTY ACID SYNTHASE; FRUCTOKINASE; FRUCTOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOPHENOL MONOOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ABDOMINAL OBESITY; BACTERIAL TRANSLOCATION; BROWN ADIPOSE TISSUE; COPPER BLOOD LEVEL; COPPER DEFICIENCY; ENZYME METABOLISM; EPICARDIAL ADIPOSE TISSUE; FRUCTOSE METABOLISM; GENETICS; HEREDITARY FRUCTOSE INTOLERANCE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER INJURY; LIVER METABOLISM; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS FAT; SUGAR INTAKE;

ANIMALS; FATTY LIVER; FRUCTOSE; HUMANS;

EID: 84859898706     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05080.x     Document Type: Review

References (94)

1. Angulo P,. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-9.
2. Law K, Brunt EM,. Nonalcoholic fatty liver disease. Clin Liver Dis 2010; 14: 591-604.
3. Vernon G, Baranova A, Younossi ZM,. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
4. Dowman JK, Tomlinson JW, Newsome PN,. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-40.
5. Smith BW, Adams LA,. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011; 48: 97-113.
6. Vanni E, Bugianesi E, Kotronen A, et al,. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-30.
7. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G,. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16: 1941-51.
8. McCullough AJ,. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl. 1): S17-29. (Pubitemid 44309539)
9. Nomura K, Yamanouchi T,. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012; 23: 203-8.
10. Castro GS, Cardoso JF, Vannucchi H, Zucoloto S, Jordão AA,. Fructose and NAFLD: metabolic implications and models of induction in rats. Acta Cir Bras 2011; 26 (Suppl. 2): 45-50.
11. Anania FA,. Non-alcoholic fatty liver disease and fructose: bad for us, better for mice. J Hepatol 2011; 55: 218-20.
12. Alisi A, Manco M, Pezzullo M, Nobili V,. Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis. Hepatology 2011; 53: 372-3.
13. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH,. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7: 251-64.
14. Nseir W, Nassar F, Assy N,. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 2579-88.
15. Stanhope KL, Havel PJ,. Fructose consumption: recent results and their potential implications. Ann N Y Acad Sci 2010; 1190: 15-24.
16. Lustig RH,. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc 2010; 110: 1307-21.
17. Tappy L, Lê KA, Tran C, Paquot N,. Fructose and metabolic diseases: new findings, new questions. Nutrition 2010; 26: 1044-9.
18. Gallagher EJ, Leroith D, Karnieli E,. The metabolic syndrome-from insulin resistance to obesity and diabetes. Med Clin North Am 2011; 95: 855-73.
19. McCullough AJ,. Epidemiology of the metabolic syndrome in the USA. J Dig Dis 2011; 12: 333-40.
20. Moore JB,. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69: 211-20.
21. Gallagher EJ, Leroith D, Karnieli E,. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med 2010; 77: 511-23.
22. Huang D, Dhawan T, Young S, et al,. Fructose impairs glucose-induced hepatic triglyceride synthesis. Lipids Health Dis 2011; 10: 20.
23. Koo HY, Wallig MA, Chung BH, et al,. Dietary fructose induces a wide range of genes with distinct shift in carbohydrate and lipid metabolism in fed and fasted rat liver. Biochim Biophys Acta 2008; 1782: 341-8.
24. Teff KL, Elliott SS, Tschöp M, et al,. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 2004; 89: 2963-72. (Pubitemid 38766393)
25. Lê KA, Tappy L,. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 2006; 9: 469-75. (Pubitemid 44097820)
26. D'Angelo G, Elmarakby AA, Pollock DM, Stepp DW,. Fructose feeding increases insulin resistance but not blood pressure in Sprague-Dawley rats. Hypertension 2005; 46: 806-11. (Pubitemid 43186756)
27. Ackerman Z, Oron-Herman M, Grozovski M, et al,. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005; 45: 1012-8. (Pubitemid 40628952)
28. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA,. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008; 295: G987-95.
29. Sánchez-Lozada LG, Mu W, Roncal C, et al,. Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. Eur J Nutr 2010; 49: 1-9.
30. Botezelli JD, Mora RF, Dalia RA, et al,. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet. Lipids Health Dis 2010; 9: 116.
31. Abdelmalek MF, Suzuki A, Guy C, et al,. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1961-71.
32. Nagai Y, Yonemitsu S, Erion DM, et al,. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab 2009; 9: 252-64.
33. Vilý L, Rebollo A, Üalsteisson GS, et al,. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 2011; 251: 32-40.
34. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD,. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106: 71-7.
35. Kimura Y, Hyogo H, Yamagishi S, et al,. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-7.
36. Chirala SS, Wakil SJ,. Structure and function of animal fatty acid synthase. Lipids 2004; 39: 1045-53. (Pubitemid 40129046)
37. Ouyang X, Cirillo P, Sautin Y, et al,. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-9.
38. Aigner E, Theurl I, Haufe H, et al,. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008; 135: 680-8.
39. Aigner E, Strasser M, Haufe H, et al,. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol 2010; 105: 1978-85.
40. Song M, Schuschke DA, Zhou Z, et al,. High fructose feeding induces copper deficiency in Sprague-Dawley rats: A novel mechanism for obesity related fatty liver. J Hepatol 2012; 56: 433-40.
41. Nelson JE, Klintworth H, Kowdley KV,. Iron metabolism in nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2012; 14: 8-16.
42. Kim BE, Nevitt T, Thiele DJ,. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol 2008; 4: 176-85. (Pubitemid 351264130)
43. Pabõn de Rozo M, Van Campen D, Miller DD,. Effects of some carbohydrates on iron absorption. Arch Latinoam Nutr 1986; 36: 688-700.
44. Fujita N, Takei Y,. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem 2011; 55: 105-32.
45. Nolan JP,. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010; 52: 1829-35.
46. Laugerette F, Vors C, Peretti N, Michalski MC,. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie 2011; 93: 39-45.
47. Bergheim I, Weber S, Vos M, et al,. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48: 983-92.
48. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I,. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-104.
49. Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, Bergheim I,. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol 2010; 298: G335-44.
50. Volynets V, Spruss A, Kanuri G, Wagnerberger S, Bischoff SC, Bergheim I,. Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res 2010; 51: 3414-24.
51. Wagnerberger S, Spruss A, Kanuri G, et al,. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2011; 10: 1-12.
52. Thuy S, Ladurner R, Volynets V, et al,. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452-5.
53. De Bandt JP, Waligora-Dupriet AJ, Butel MJ,. Intestinal microbiota in inflammation and insulin resistance: relevance to humans. Curr Opin Clin Nutr Metab Care 2011; 14: 334-40.
54. Ibrahim MM,. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010; 11: 11-8.
55. Rodríguez A, Catalán V, Gõmez-Ambrosi J, Frühbeck G,. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 2007; 13: 2169-75. (Pubitemid 47074048)
56. Ness-Abramof R, Apovian CM,. Waist circumference measurement in clinical practice. Nutr Clin Pract 2008; 23: 397-404.
57. Sogabe M, Okahisa T, Hibino S, Yamanoi A,. Usefulness of differentiating metabolic syndrome into visceral fat type and subcutaneous fat type using ultrasonography in Japanese males. J Gastroenterol 2012; 47: 293-9.
58. Eguchi Y, Mizuta T, Sumida Y, et al,. The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol 2011; 6 (Suppl. 1): 70-8.
59. Jun DW, Han JH, Kim SH, et al,. Association between low thigh fat and non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2008; 23: 888-93. (Pubitemid 351806576)
60. O'Connell J, Lynch L, Cawood TJ, et al,. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 2010; 5: e9997.
61. Stanhope KL, Havel PJ,. Fructose consumption: considerations for future research on its effects on adipose distribution, lipid metabolism, and insulin sensitivity in humans. J Nutr 2009; 139: 1236S-41S.
62. Silbernagel G, Machann J, Unmuth S, et al,. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br J Nutr 2011; 106: 79-86.
63. Pollock NK, Bundy V, Kanto W, et al,. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. J Nutr 2012; 142: 251-7.
64. Odegaard AO, Choh AC, Czerwinski SA, Towne B, Demerath EW,. Sugar-sweetened and diet beverages in relation to visceral adipose tissue. Obesity (Silver Spring) 2012; 20: 689-91.
65. Iacobellis G, Willens HJ,. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009; 22: 1311-9.
66. Guaraldi G, Scaglioni R, Zona S, et al,. Epicardial adipose tissue is an independent marker of cardiovascular risk in HIV-infected patients. AIDS 2011; 25: 1199-205.
67. Scher AM,. Absence of atherosclerosis in human intramyocardial coronary arteries: a neglected phenomenon. Atherosclerosis 2000; 149: 1-3. (Pubitemid 30125965)
68. Sacks HS, Fain JN,. Human epicardial adipose tissue: a review. Am Heart J 2007; 153: 907-17. (Pubitemid 46809849)
69. Yilmaz Y, Kurt R, Gurdal A, et al,. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 2011; 217: 125-9.
70. Axelsen LN, Lademann JB, Petersen JS, et al,. Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1560-70.
71. Lidell ME, Enerbäck S,. Brown adipose tissue-a new role in humans? Nat Rev Endocrinol 2010; 6: 319-25.
72. Ravussin E, Galgani JE,. The implication of brown adipose tissue for humans. Annu Rev Nutr 2011; 31: 33-47.
73. Tews D, Wabitsch M,. Renaissance of brown adipose tissue. Horm Res Paediatr 2011; 75: 231-9.
74. Vijgen GH, Bouvy ND, Teule GJ, et al,. Brown adipose tissue in morbidly obese subjects. PLoS One 2011; 6: e17247.
75. Pace L, Nicolai E, D'Amico D, et al,. Determinants of physiologic 18F-FDG uptake in brown adipose tissue in sequential PET/CT examinations. Mol Imaging Biol 2011; 13: 1029-35.
76. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al,. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009; 360: 1500-8.
77. Yilmaz Y, Ones T, Purnak T, et al,. Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans. Aliment Pharmacol Ther 2011; 34: 318-23.
78. Boll M, Weber LW, Stampfl A,. Nutritional regulation of the activities of lipogenic enzymes of rat liver and brown adipose tissue. Z Naturforsch C 1996; 51: 859-69. (Pubitemid 27058786)
79. Young JB, Weiss J, Boufath N,. Effects of dietary monosaccharides on sympathetic nervous system activity in adipose tissues of male rats. Diabetes 2004; 53: 1271-8. (Pubitemid 38569013)
80. Wong D,. Hereditary fructose intolerance. Mol Genet Metab 2005; 85: 165-7.
81. Bouteldja N, Timson DJ,. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis 2010; 33: 105-12.
82. Gaby AR,. Adverse effects of dietary fructose. Altern Med Rev 2005; 10: 294-306. (Pubitemid 41803484)
83. Semba RD, Nicklett EJ, Ferrucci L,. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci 2010; 65: 963-75.
84. Unoki H, Yamagishi S,. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008; 14: 987-9. (Pubitemid 351753287)
85. Gaens KH, Niessen PM, Rensen SS, et al,. Endogenous formation of N(Îμ)-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol 2012; 56: 647-55.
86. Geroldi D, Falcone C, Emanuele E,. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-8.
87. Yilmaz Y, Ulukaya E, Gul OO, et al,. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009; 42: 802-7.
88. Takeuchi M, Iwaki M, Takino J, et al,. Immunological detection of fructose-derived advanced glycation end-products. Lab Invest 2010; 90: 1117-27.
89. Bray GA, Nielsen SJ, Popkin BM,. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004; 79: 537-43. (Pubitemid 41103894)
90. Ferder L, Ferder MD, Inserra F,. The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr Hypertens Rep 2010; 12: 105-12.
91. Lasater G, Piernas C, Popkin BM,. Beverage patterns and trends among school-aged children in the US, 1989-2008. Nutr J 2011; 10: 103.
92. Burton-Freeman B,. Postprandial metabolic events and fruit-derived phenolics: a review of the science. Br J Nutr 2010; 104 (Suppl. 3): S1-14.
93. Bose T, Chakraborti AS,. Fructose-induced structural and functional modifications of hemoglobin: implication for oxidative stress in diabetes mellitus. Biochim Biophys Acta 2008; 1780: 800-8.
94. Schulze MB, Manson JE, Ludwig DS, et al,. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 2004; 292: 927-34. (Pubitemid 39097202)